Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statement Of Cash flows (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net Income (Loss)		$ 5,713	$ 19,786	$ 9,009	$ 35,123
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				33,884	31,473
Amortization of debt discount and issuance costs				7,727	914
Stock-based compensation		9,879	5,483	18,655	12,737
Deferred income taxes, net				(3,753)	(2,053)
Contingent consideration		0	1,791	0	3,026
Non-cash interest income				0	(2,023)
Operating lease right of use assets amortization	[1]			8,716	6,487
Other				103	849
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				(1,245)	(4,606)
Inventories				10,474	(2,508)
Prepaid expenses and other assets				457	(12,879)
Other assets				364	(888)
Accounts payable				1,547	(3,871)
Accrued expenses				2,259	(11,769)
Operating lease liabilities				(1,198)	(4,544)
Long-term liabilities				(101)	154
Total cash provided by operating activities				86,898	45,622
Cash flows from investing activities:
Acquisitions, net of cash acquired				0	(28,099)
Proceeds from maturity of marketable securities held to maturity				0	102,323
Additions to capitalized software costs				(2,619)	(2,075)
Purchases of property, plant and equipment				(13,154)	(16,749)
Other investing activities				11	0
Total cash (used in) provided by investing activities				(15,762)	55,400
Cash flows from financing activities:
Proceeds from exercise of stock options				1,788	62
Payment of tax withholding obligation on vesting of restricted stock				(8,857)	(11,140)
Payment of earnout consideration				(7,375)	(7,298)
Other financing activities				(303)	(12)
Total cash used in financing activities				(14,747)	(18,388)
Effect of exchange rate changes on cash and cash equivalents				1,434	(2,436)
Net increase in cash and cash equivalents				57,823	80,198
Cash, cash equivalents, beginning of period				751,323	523,458
Cash and cash equivalents, end of period		809,146	$ 603,656	809,146	603,656
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				23,860	831
Fair value of shares of common stock issued for contingent consideration earnouts				5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition				0	$ 5,243
As Previously Reported
Cash flows from operating activities:
Net Income (Loss)		3,321		5,415
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				33,648
Amortization of debt discount and issuance costs				7,727
Stock-based compensation				17,990
Deferred income taxes, net				(2,634)
Contingent consideration		0		0
Operating lease right of use assets amortization				(16,349)
Other				(172)
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				(1,245)
Inventories				10,474
Prepaid expenses and other assets				(1,999)
Other assets				364
Accounts payable				1,547
Accrued expenses				8,366
Operating lease liabilities				23,867
Long-term liabilities				(101)
Total cash provided by operating activities				86,898
Cash flows from investing activities:
Additions to capitalized software costs				(2,619)
Purchases of property, plant and equipment				(13,154)
Other investing activities				11
Total cash (used in) provided by investing activities				(15,762)
Cash flows from financing activities:
Proceeds from exercise of stock options				1,788
Payment of tax withholding obligation on vesting of restricted stock				(8,857)
Payment of earnout consideration				(7,375)
Other financing activities				(303)
Total cash used in financing activities				(14,747)
Effect of exchange rate changes on cash and cash equivalents				1,434
Net increase in cash and cash equivalents				57,823
Cash, cash equivalents, beginning of period				751,323
Cash and cash equivalents, end of period		809,146		809,146
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				23,860
Fair value of shares of common stock issued for contingent consideration earnouts				5,742
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)		3,009		4,407
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				0
Amortization of debt discount and issuance costs				0
Stock-based compensation				0
Deferred income taxes, net				(1,000)
Contingent consideration		0		0
Operating lease right of use assets amortization				0
Other				0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				0
Inventories				0
Prepaid expenses and other assets				2,700
Other assets				0
Accounts payable				0
Accrued expenses				(6,107)
Operating lease liabilities				0
Long-term liabilities				0
Total cash provided by operating activities				(0)
Cash flows from investing activities:
Additions to capitalized software costs				0
Purchases of property, plant and equipment				0
Other investing activities				0
Total cash (used in) provided by investing activities				0
Cash flows from financing activities:
Proceeds from exercise of stock options				0
Payment of tax withholding obligation on vesting of restricted stock				0
Payment of earnout consideration				0
Other financing activities				0
Total cash used in financing activities				0
Effect of exchange rate changes on cash and cash equivalents				0
Net increase in cash and cash equivalents				(0)
Cash, cash equivalents, beginning of period				0
Cash and cash equivalents, end of period		(0)		(0)
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				0
Fair value of shares of common stock issued for contingent consideration earnouts				0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)		(617)		(813)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				236
Amortization of debt discount and issuance costs				0
Stock-based compensation				665
Deferred income taxes, net				(119)
Contingent consideration		0		0
Operating lease right of use assets amortization				25,065
Other				275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				0
Inventories				0
Prepaid expenses and other assets				(244)
Other assets				0
Accounts payable				0
Accrued expenses				0
Operating lease liabilities				(25,065)
Long-term liabilities				0
Total cash provided by operating activities				0
Cash flows from investing activities:
Additions to capitalized software costs				0
Purchases of property, plant and equipment				0
Other investing activities				0
Total cash (used in) provided by investing activities				0
Cash flows from financing activities:
Proceeds from exercise of stock options				0
Payment of tax withholding obligation on vesting of restricted stock				0
Payment of earnout consideration				0
Other financing activities				0
Total cash used in financing activities				0
Effect of exchange rate changes on cash and cash equivalents				0
Net increase in cash and cash equivalents				0
Cash, cash equivalents, beginning of period				0
Cash and cash equivalents, end of period		$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				0
Fair value of shares of common stock issued for contingent consideration earnouts				$ 0

[1] *Amounts reclassified in the current presentation from a component of “Changes in operating assets and liabilities” to a component of “Adjustments to reconcile net income.” The reclassification did not result in any change to total cash provided by operating activities.